...
kod-img

Kodiak Sciences Inc, Common Stock

KOD

NMQ

$8.65

-$0.03

(-0.35%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$456.77M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
317.81K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.19 L
$11.6 H
$8.65

About Kodiak Sciences Inc, Common Stock

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKODSectorS&P500
1-Week Return2.13%-2.12%-3%
1-Month Return49.4%-3.42%-0.73%
3-Month Return227.65%-11.13%2.87%
6-Month Return243.25%-5.74%7.17%
1-Year Return210.04%3.97%25.31%
3-Year Return-90.24%1.05%28.38%
5-Year Return-87.1%34.37%81.89%
10-Year Return-14.86%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue911.00K4.21M8.71M11.00M25.95M[{"date":"2019-12-31","value":3.51,"profit":true},{"date":"2020-12-31","value":16.22,"profit":true},{"date":"2021-12-31","value":33.57,"profit":true},{"date":"2022-12-31","value":42.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(911.00K)(4.21M)(8.71M)(11.00M)(25.95M)[{"date":"2019-12-31","value":-91100000,"profit":false},{"date":"2020-12-31","value":-420800000,"profit":false},{"date":"2021-12-31","value":-871100000,"profit":false},{"date":"2022-12-31","value":-1100100000,"profit":false},{"date":"2023-12-31","value":-2594700000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses49.19M136.01M267.05M341.38M277.32M[{"date":"2019-12-31","value":14.41,"profit":true},{"date":"2020-12-31","value":39.84,"profit":true},{"date":"2021-12-31","value":78.23,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.24,"profit":true}]
Operating Income(49.19M)(136.01M)(267.05M)(341.38M)(277.32M)[{"date":"2019-12-31","value":-4919000000,"profit":false},{"date":"2020-12-31","value":-13600700000,"profit":false},{"date":"2021-12-31","value":-26705100000,"profit":false},{"date":"2022-12-31","value":-34137900000,"profit":false},{"date":"2023-12-31","value":-27732100000,"profit":false}]
Total Non-Operating Income/Expense3.38M5.79M337.00K14.61M33.55M[{"date":"2019-12-31","value":10.09,"profit":true},{"date":"2020-12-31","value":17.25,"profit":true},{"date":"2021-12-31","value":1,"profit":true},{"date":"2022-12-31","value":43.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(47.37M)(133.10M)(266.99M)(333.82M)(260.49M)[{"date":"2019-12-31","value":-4736500000,"profit":false},{"date":"2020-12-31","value":-13309600000,"profit":false},{"date":"2021-12-31","value":-26699000000,"profit":false},{"date":"2022-12-31","value":-33382300000,"profit":false},{"date":"2023-12-31","value":-26049100000,"profit":false}]
Income Taxes(638.00K)2.73M(153.56K)7.35M-[{"date":"2019-12-31","value":-8.69,"profit":false},{"date":"2020-12-31","value":37.16,"profit":true},{"date":"2021-12-31","value":-2.09,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(46.73M)(135.83M)(266.84M)(341.17M)-[{"date":"2019-12-31","value":-4672700000,"profit":false},{"date":"2020-12-31","value":-13582570300,"profit":false},{"date":"2021-12-31","value":-26683644200,"profit":false},{"date":"2022-12-31","value":-34116851500,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(47.37M)(133.10M)(266.99M)(333.82M)(260.49M)[{"date":"2019-12-31","value":-4736500000,"profit":false},{"date":"2020-12-31","value":-13309600000,"profit":false},{"date":"2021-12-31","value":-26699000000,"profit":false},{"date":"2022-12-31","value":-33382300000,"profit":false},{"date":"2023-12-31","value":-26049100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(46.73M)(133.10M)(266.99M)(333.82M)(260.49M)[{"date":"2019-12-31","value":-4672700000,"profit":false},{"date":"2020-12-31","value":-13309600000,"profit":false},{"date":"2021-12-31","value":-26699000000,"profit":false},{"date":"2022-12-31","value":-33382300000,"profit":false},{"date":"2023-12-31","value":-26049100000,"profit":false}]
EPS (Diluted)(1.25)(2.89)(5.15)(6.39)(4.96)[{"date":"2019-12-31","value":-125,"profit":false},{"date":"2020-12-31","value":-289,"profit":false},{"date":"2021-12-31","value":-515,"profit":false},{"date":"2022-12-31","value":-639,"profit":false},{"date":"2023-12-31","value":-496,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KOD
Cash Ratio 8.22
Current Ratio 8.42

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KOD
ROA (LTM) -26.72%
ROE (LTM) -71.50%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KOD
Debt Ratio Lower is generally better. Negative is bad. 0.50
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.50

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KOD
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.46
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Kodiak Sciences Inc share price today?

Kodiak Sciences Inc (KOD) share price today is $8.65

Can Indians buy Kodiak Sciences Inc shares?

Yes, Indians can buy shares of Kodiak Sciences Inc (KOD) on Vested. To buy Kodiak Sciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KOD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kodiak Sciences Inc be purchased?

Yes, you can purchase fractional shares of Kodiak Sciences Inc (KOD) via the Vested app. You can start investing in Kodiak Sciences Inc (KOD) with a minimum investment of $1.

How to invest in Kodiak Sciences Inc shares from India?

You can invest in shares of Kodiak Sciences Inc (KOD) via Vested in three simple steps:

  • Click on Sign Up or Invest in KOD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kodiak Sciences Inc shares
What is Kodiak Sciences Inc 52-week high and low stock price?

The 52-week high price of Kodiak Sciences Inc (KOD) is $11.6. The 52-week low price of Kodiak Sciences Inc (KOD) is $2.19.

What is Kodiak Sciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Kodiak Sciences Inc (KOD) is

What is Kodiak Sciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kodiak Sciences Inc (KOD) is 2.46

What is Kodiak Sciences Inc dividend yield?

The dividend yield of Kodiak Sciences Inc (KOD) is 0.00%

What is the Market Cap of Kodiak Sciences Inc?

The market capitalization of Kodiak Sciences Inc (KOD) is $456.77M

What is Kodiak Sciences Inc’s stock symbol?

The stock symbol (or ticker) of Kodiak Sciences Inc is KOD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top